Renaissance Technologies’s Generate Biomedicines GENB Stock Holding History

Renaissance Technologies’s Portfolio GENB Stock Details GENB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$669K	Buy	+39,685	New	+$541K	﹤0.01%	2491

Other funds holding GENB

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Renaissance Technologies's GENB Position: Q2 2026 in Review

Renaissance Technologies opened a new position in Generate Biomedicines (GENB) in Q2 2026: 39,685 shares worth $669K. The stake represents ﹤0.01% of the portfolio and ranks #2491 among its holdings.

86 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

Renaissance Technologies held 39,685 shares of Generate Biomedicines worth $669K as of Q2 2026.
Generate Biomedicines was a new Renaissance Technologies position in Q2 2026.
Generate Biomedicines made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2491 holding.
86 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.